These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 26218678

  • 21. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
    Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC, LUCID trial investigators.
    Br J Haematol; 2014 Nov; 167(4):466-77. PubMed ID: 25130401
    [Abstract] [Full Text] [Related]

  • 22. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ, Xu W, Qian SX, Wu YJ, Hong M, Chen LJ, Wu HX, Lu H, Qiu HX, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [Abstract] [Full Text] [Related]

  • 23. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
    Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG.
    Blood; 2011 Mar 17; 117(11):3016-24. PubMed ID: 21245487
    [Abstract] [Full Text] [Related]

  • 24. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.
    J Clin Oncol; 2010 Apr 01; 28(10):1756-65. PubMed ID: 20194844
    [Abstract] [Full Text] [Related]

  • 25. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG.
    Blood; 2011 Aug 25; 118(8):2062-8. PubMed ID: 21750315
    [Abstract] [Full Text] [Related]

  • 26. Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.
    Joffe E, Ariela Arad N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Goldschmidt N, Polliack A, Herishanu Y.
    Hematol Oncol; 2018 Feb 25; 36(1):128-135. PubMed ID: 28639416
    [Abstract] [Full Text] [Related]

  • 27. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
    Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M.
    Blood; 2016 Jan 14; 127(2):208-15. PubMed ID: 26486789
    [Abstract] [Full Text] [Related]

  • 28. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
    Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S.
    Cancer; 2014 Nov 15; 120(22):3494-501. PubMed ID: 25043749
    [Abstract] [Full Text] [Related]

  • 29. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
    Li Z, Li F, Yi S, Gu Z, Yu Z, Xu Y, Feng X, Liu W, Zou D, Qi J, Zhan F, Qiu L.
    BMC Cancer; 2015 Jul 29; 15():555. PubMed ID: 26219471
    [Abstract] [Full Text] [Related]

  • 30. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ.
    Cancer; 2003 Apr 01; 97(7):1711-20. PubMed ID: 12655528
    [Abstract] [Full Text] [Related]

  • 31. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV.
    Lancet Oncol; 2019 Nov 01; 20(11):1576-1586. PubMed ID: 31582354
    [Abstract] [Full Text] [Related]

  • 32. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
    Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S.
    Cancer; 2013 Nov 01; 119(21):3805-11. PubMed ID: 23943357
    [Abstract] [Full Text] [Related]

  • 33. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P.
    Leukemia; 2017 Oct 01; 31(10):2085-2093. PubMed ID: 28216660
    [Abstract] [Full Text] [Related]

  • 34. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
    Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG.
    Oncotarget; 2017 Mar 28; 8(13):22104-22112. PubMed ID: 27655665
    [Abstract] [Full Text] [Related]

  • 35. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA, da Silva AS, Souza KM, Koury Cde N, de Mello LM.
    Crit Rev Oncol Hematol; 2015 Jun 28; 94(3):261-9. PubMed ID: 25797826
    [Abstract] [Full Text] [Related]

  • 36. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE, Rai KR, O'Brien S.
    Clin Adv Hematol Oncol; 2006 Nov 28; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [Abstract] [Full Text] [Related]

  • 37. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
    Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M.
    J Clin Oncol; 2005 Jun 20; 23(18):4070-8. PubMed ID: 15767647
    [Abstract] [Full Text] [Related]

  • 38. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
    Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L.
    Invest New Drugs; 2012 Jun 20; 30(3):1232-40. PubMed ID: 21922186
    [Abstract] [Full Text] [Related]

  • 39. Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.
    Lew TE, Cheah CY, Carney DA, Prince HM, Wolf M, Bazargan A, Januszewicz EH, Filshie R, Westerman D, Seymour JF, Tam CS.
    Leuk Lymphoma; 2016 May 20; 57(5):1044-53. PubMed ID: 26464106
    [Abstract] [Full Text] [Related]

  • 40. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C, NCRI CLL Sub-Group.
    Br J Haematol; 2011 Mar 20; 152(5):570-8. PubMed ID: 21231927
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.